Ani Pharmaceutic SEC Filings

Antonio R. Pera, a director of ANI Pharmaceuticals, Inc. (ANIP), reported a sale of 7,292 shares of the company on 09/03/2025 at a price of $94.94 per share. After the transaction, Mr. Pera beneficially owned 22,660 shares. The Form 4 was signed by an attorney-in-fact and filed following the transaction.

Form 144 notice for ANI Pharmaceuticals, Inc. (ANIP) reports a proposed sale of 7,292 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $692,270.40 and stated approximate sale date of 09/03/2025. The filer identifies prior restricted stock acquisitions of 3,000 shares on 04/27/2023 and 4,292 shares on 03/23/2022, both received from the issuer, and discloses a sale during the past three months of 5,421 shares for $486,406.81 on 08/20/2025. The form includes the standard representation that the seller is not aware of any undisclosed material adverse information.

Insider sale disclosed on Form 4 for ANI Pharmaceuticals, Inc. (ANIP). The filing shows that Matthew J. Leonard, reported as a director, sold 2,528 shares of ANIP common stock on 08/25/2025 at a reported price of $90.62 per share. After the sale, Mr. Leonard beneficially owned 6,864 shares, reported as direct ownership. The Form 4 was signed by attorney-in-fact Meredith W. Cook on 08/26/2025. No derivative transactions or additional remarks are included in the filing.

ANI Pharmaceuticals (ANIP) Form 144 notice shows a proposed sale of 2,528 restricted common shares by or for an identified person through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $229,075.98 and an approximate sale date of 08/25/2025. The filing states those shares were acquired as restricted stock from the issuer on 08/21/2025 and paid for on that date. The form also discloses a separate sale by Matthew Leonard of 6,937 common shares on 08/18/2025 with gross proceeds of $611,644.31. The filer certifies they have no undisclosed material adverse information.

Krista Davis, SVP and Chief HR Officer of ANI Pharmaceuticals, Inc. (ANIP), reported the sale of 1,763 shares of ANI common stock on 08/22/2025. The shares were sold in multiple trades at prices ranging from $91.01 to $91.19, with a weighted average sales price reported as $91.10. After the transaction, Ms. Davis beneficially owned 62,896 shares. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 08/25/2025. The filing identifies the reporter as an officer (SVP, Chief HR Officer).

ANI Pharmaceuticals insider sale by Shanmugam Muthusamy — The filing shows the company director and Head of R&D/COO-Novitium Ops executed sales of ANI Pharmaceuticals (ANIP) common stock on August 20–21, 2025. On 08/20/2025 the reporting person sold 47,012 shares at a weighted average price of $90.27, and on 08/21/2025 sold 52,988 shares at a weighted average price of $90.44. After these transactions the reporting person retained indirect beneficial ownership of 431,920 shares through Esjay LLC and an additional 5,000 shares held by SS Pharma LLC, with voting and dispositive power over those LLC-held shares. The form is signed by attorney-in-fact Meredith W. Cook.

ANI Pharmaceuticals' Schedule 13D/A reports that Meridian Venture Partners II entities and affiliated persons beneficially own a combined 1,034,570 shares of ANI common stock, representing 4.8% of the class. The filing breaks ownership across Meridian Venture Partners II GP, L.P., Meridian Venture Partners II, L.P., Meridian Venture Partners II, Co., and Robert E. Brown, Jr., with shared voting and dispositive power over 1,014,381 shares held by the Meridian entities and sole voting/dispositive power over 20,189 shares held directly by Mr. Brown.

The statement provides the issuer's principal office address and is signed by Robert E. Brown, Jr. as of 08/21/2025. No additional transaction details, intentions regarding the investment, or legal proceedings are disclosed in the provided excerpt.

Form 144 filed for ANIP insider sales The filing notifies proposed and recent sales of ANI Pharmaceuticals common stock by an insider. A proposed sale of 52,988 shares through Merrill Lynch on NASDAQ is listed with an aggregate market value of $4,792,058.06 and an approximate sale date of 08/21/2025. The shares were acquired on 11/19/2021 in a company buyout and listed as a compensatory payment. The filing also reports three recent sales by Muthusamy Shanmugam on 08/14/2025, 08/15/2025, and 08/20/2025 totaling 147,012 shares with gross proceeds reported for each sale. The filer certifies no undisclosed material adverse information.